Emerging biomarkers for cancer immunotherapy in melanoma
- 1 October 2018
- journal article
- review article
- Published by Elsevier BV in Seminars in Cancer Biology
- Vol. 52, 207-215
- https://doi.org/10.1016/j.semcancer.2017.09.004
Abstract
No abstract availableKeywords
This publication has 67 references indexed in Scilit:
- Pembrolizumab versus Ipilimumab in Advanced MelanomaThe New England Journal of Medicine, 2015
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunityNature, 2015
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience, 2015
- Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune TherapiesCancer Immunology Research, 2015
- Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-AnalysisJournal of Clinical Oncology, 2015
- Genetic Basis for Clinical Response to CTLA-4 Blockade in MelanomaThe New England Journal of Medicine, 2014
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature, 2014
- PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 2014
- Mismatch repair protein expression and microsatellite instability: a comparison of clear cell sarcoma of soft parts and metastatic melanomaLaboratory Investigation, 2006
- Allele loss on chromosome 11q and microsatellite instability in malignant melanomaEuropean Journal of Cancer, 1996